Mechanisms Behind the Disease: Understanding the Role of APRIL in IgAN Pathogenesis: A Podcast.
文献摘要
This podcast provides an overview of immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide and a progressive, immune-mediated chronic kidney disease (CKD) often diagnosed in early to mid-adulthood. Patients face heterogeneous presentations ranging from asymptomatic disease to proteinuria and hematuria leading to rapid loss of kidney function, with many progressing to kidney failure within a decade. Beyond renal effects, IgAN imposes substantial quality-of-life burdens, particularly affecting individuals of childbearing potential. The pathogenesis of IgAN is best explained by the four-hit process involving the overproduction of galactose-deficient immunoglobulin A1 (Gd-IgA1), development of anti-Gd-IgA1 autoantibodies, immune complex formation, and mesangial deposition of immune complexes, leading to complement activation and glomerular injury. Central to this process is dysregulated B cell activation, differentiation, and immunoglobulin class switching. A proliferation-inducing ligand (APRIL), a member of the tumor necrosis factor superfamily, promotes pathogenic IgA1 production through plasma cell survival and IgA class switching. Genetic, preclinical, and clinical evidence implicates APRIL as a key driver of IgAN pathophysiology. Management strategies such as using renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter 2 inhibitors focus on supportive care and mitigation of generic CKD drivers but do not directly address upstream immune mechanisms, leaving many patients at risk for irreversible nephron loss. With the 2025 Kidney Disease: Improving Global Outcomes guidelines, the treatment of IgAN is evolving toward earlier, proactive management that simultaneously targets IgA immune complex-mediated injury and the long-term consequences of CKD. Emerging insights into APRIL-driven pathways support the development of targeted therapies that may selectively reduce pathogenic IgA production while preserving protective immune function, offering a promising strategy to address the underlying disease mechanism and improve long-term outcomes and quality of life in patients with IgAN.